Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 101Specimen Handling 83pembrolizumab 76enzalutamide 63Nivolumab 59Gemcitabine 56Docetaxel 50apalutamide 42Radiosurgery 42Abiraterone Acetate 40Prednisone 39Androgen Antagonists 39Cisplatin 37Biopsy 37darolutamide 36cabozantinib 32Radiotherapy 32Pluvicto 28Carboplatin 28abiraterone 27Ipilimumab 25enfortumab vedotin 24durvalumab 24Radiation 23atezolizumab 22X-Rays 21Leuprolide 20Standard of Care 19olaparib 18avelumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cell Count × Genitourinary × 90 days × Clear all
NCT06318871 2026-05-11

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
5 enrolled
Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡